Podoplanin is a useful prognostic marker and indicates better differentiation in lung squamous cell cancer patients? A systematic review and meta-analysis
Open Access
- 14 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-11
- https://doi.org/10.1186/s12885-020-06936-9
Abstract
BackgroundThe CSC (cancer stem cell) markers often indicate poor prognosis and more cell invasion or migration of cancer patients. Podoplanin was assumed as a candidate CSC marker and predict poor prognosis among squamous cancers. Whereas, the prognostic value of podoplanin among lung squamous cancer (LUSC) patients remains controversial.MethodsA search of databases including PubMed, Embase and Web of Science was performed. Eligible articles studying the prognostic significance of podoplanin were selected. Odds ratio and HR (hazard ratio) were used to assess the relationships between podoplanin and clinical characteristics, as well as to quantify its prognostic role. The heterogeneity was estimated by I-2 Statistic and P values from sensitivity analysis. Begg's funnel plots were used to estimate possible publication bias.Results8 eligible studies containing 725 I-IV LUSC patients were included. Podoplanin expression showed no significant correlations with TNM stage, vascular invasion, lymphatic invasion, lymph node metastasis, pleural metastasis of tumor and gender of patients. However, podoplanin showed significant associations with better differentiation (pooled OR=2.64, 95% CI 1.53-4.56, P=0.0005, fixed effect) and better overall survival (HR=2.14, 95% CI 1.45-3.15, P=0.0001, fixed effect) and progression-free survival (HR=1.73, 95% CI: 1.01-2.98, P=0.05, fixed effect) of LUSC. Funnel plots illustrated no evidence of publication bias in our results.ConclusionsPodoplanin could be a useful prognostic marker and indicates better differentiation for LUSC patients, and the value of PDPN expression as a marker for cancer stem cells in LUSC should be critically evaluated in future studies.This publication has 38 references indexed in Scilit:
- Podoplanin-mediated cell adhesion through extracellular matrix in oral squamous cell carcinomaLaboratory Investigation, 2013
- Podoplanin: emerging functions in development, the immune system, and cancerFrontiers in Immunology, 2012
- Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cellsMolecular Cancer, 2010
- The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancerLung Cancer, 2010
- Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell CarcinomaAnnals of Surgical Oncology, 2010
- Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lungCancer Science, 2009
- Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431Biochemical and Biophysical Research Communications, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiationLaboratory Investigation, 2007
- Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiationLaboratory Investigation, 2006